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Abstract 
Aspirin has been used as anti-inflammatory and anti-aggregate for decades but the precise mechanism(s) 
of action after the presence of the toxic peptide Aβ1-42 in cultured astrocytes remains poorly resolved. 
Here we use low-doses of aspirin (10-7 M) in astrocytes in primary culture in presence or absence of 
Aβ1-42 toxic peptide. We noted an increase of cell viability and proliferation with or without Aβ1-42 peptide 
presence in aspirin treated cells. In addition, a decrease in apoptosis, determined by Caspase 3 activity 
and the expression of Cyt c and Smac/Diablo, were detected. Also, aspirin diminished necrosis process 
(LDH levels), pro-inflammatory mediators (IL-β and TNF-α) and NF-ᴋB protein expression, increasing 
anti-inflammatory PPAR-γ protein expression, preventing Aβ1-42 toxic effects. Aspirin inhibited COX-2 
and iNOS without changes in COX-1 expression, increasing anti-oxidant protein (Cu/Zn-SOD and 
Mn-SOD) expression in presence or absence of Aβ1-42. Taken together, our results show that aspirin, at 
low doses increases cell viability by decreasing inflammation and oxidative stress, preventing the 
deleterious effects of the Aβ1-42 peptide on astrocytes in primary culture. The use of low doses of aspirin 
may be more suitable for Alzheimer's disease. 
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Introduction 
Alzheimer’s disease (AD) causes decline in 
memory and is the most common neurodegenerative 
disease implicated in the aging process [1]. The 
prominent features of AD include amyloid plaques, 
intraneuronal tangles, cell death, inflammatory 
changes and oxidative stress [2,3,4].  
Astroglia are the most prevalent cell type in the 
brain [5]. These cells have roles in the brain protecting 
against CNS injury and repairing nervous tissue after 
injury [6]. Data from our laboratory demonstrated 
that astrocytes increase neuronal viability and 
mitochondrial biogenesis, protecting from oxidative 
stress and inflammation induced by toxic amyloid 
peptide [7,8]. Also, astrocytes act in neuronal 
synapses, regulate the blood-brain barrier, providing 
nutrients to the nervous system and maintaining ion 
and metabolite balance, and also propagate calcium 
currents, release gliotransmitters, growth factors and 
inflammatory mediators [9,10,11]. Astrogliosis is 
produced by a reaction from astrocytes to 
inflammation, oxidative stress and cell death 
producing toxic products and inflammatory agents 
and oxidative stress mediators [3,12]. In astrocytes, 
complex changes and specific conflicts occur in 
different brain regions during the development of 








AD, phagocytizing and reducing amyloid β (Aβ) 
deposition because these cells surround amyloid 
plaques and secrete proinflammatory factors [13,14]. 
Acetylsalicylic acid (aspirin) is used frequently 
as a member of the nonsteroidal anti-inflammatory 
drugs (NSAIDs) group [15]. Aspirin induces its effects 
by inhibiting cyclooxygenase (COX) and suppresses 
prostaglandins [16,17]. Two main isoforms of COX 
exist, COX-1 and COX-2. COX-1 is involved in the 
synthesis of thromboxane A2 (TXA2) [18] and COX-2 
in prostacyclin biosynthesis [19,20]. In 
epidemiological studies of AD, a high dose of aspirin 
produces lower prevalence of AD [21] (Nilsson et al. 
2003). Other authors using low-dose aspirin treatment 
indicated promising results for aspirin [22]. In this 
study, we were interested in exploring the action of 
aspirin in both inflammatory and ROS (reactive 
oxygen species) events associated with Alzheimer’s 
disease (AD) by using the amyloid β1-42 in astrocytes 
in primary culture. The accumulation and 
precipitation of Aβ1-42 peptide has a 
neuropathological role associated with AD. However 
the Aβ40-1 peptide has non-toxic effects and is used as 
control. 
Material and Methods 
Materials 
This study was approved by the Bioethics 
Committee of the School of Medicine of the University 
of Valencia, and the local Government of Valencia, 
Spain (2016/VSC/PEA/00220). All animals (Wilson 
rats from Charles River laboratory) were handled 
according to the recommendations of the Committee 
and with access to food and water. Animals were 
sacrificed with pentobarbital by the veterinary 
personnel. No randomization was performed to 
allocate subjects in the study. Rats (6 months old) 
were housed alone for 21 days during pregnancy. 
Female rat fetuses were obtained at day 21 of 
pregnancy prior to delivery. The fetal cortex was 
obtained to create a culture of astrocytes. Every assay 
was performed 3, 4 or 5 times, from different mother 
rats. No blinding procedures for each culture were 
made. Female rats were excluded if they were 
pregnant before the study. Rats were also excluded if 
the delivery of rats was 21 days before pregnancy.  
Dulbecco’s modified Eagle’s medium (DMEM) 
and fetal bovine serum (FBS) were obtained from 
Gibco (Gibco Invitrogen Corporation, Barcelona, 
Spain). The oligomers Aβ (40-1 and 1-42), were 
prepared following manufacturer’s instructions 
(Sigma-Aldrich biotechnology). Briefly, the peptides 
were dissolved in 100 µM phosphate buffered saline 
(PBS) and preparations were heated for 24 h at 37°C 
for assembly of the oligomers. Aspirin was obtained 
from Sigma-Aldrich biotechnology and dissolved in 
Krebs solution to the proper final concentration (10-7 
M). 3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheniyl-2H- 
tetrazolium bromide (MTT) was purchased from 
Sigma Chemical Co. (St Louis, MO). Enzyme-linked 
immunosorbent assay (ELISA) kits for IL-1β 
(Interleukin 1-β) and TNF-α (Tumor necrosis-α) from 
Pierce Biotechnology, Inc. (Rockford, USA). Western 
Blot Chemiluminescent Detection System (ECL) was 
from Amersham (Amersham Biosciences, Barcelona, 
Spain). Monoclonal anti-cytochrome C (Cyt c) 
antibody (1:500), monoclonal anti-Smac/Diablo 
antibody (Smac/Diablo) (1:500), monoclonal anti- 
nuclear factor κB antibody (NF-κB) (1:1000), 
monoclonal anti-Mn superoxide dismutase antibody 
(Mn-SOD) (1:500), monoclonal anti-cyclooxygenase 1 
antibody (COX-1) (1:500), monoclonal anti- 
cyclooxygenase 2 antibody (COX-2) (1:500), 
monoclonal anti-inducible nitric oxide synthase 
antibody (iNOS) (1:500) from Santa Cruz 
Biotechnology (Madrid, Spain). Monoclonal anti- 
peroxisome proliferator-activated receptor antibody 
(PPAR-γ) (1:500) from Sigma Aldrich (Madrid, Spain). 
Polyclonal anti-Cu/Zn superoxide dismutase 
antibody (Cu/Zn-SOD) (1:500) from Assay Designs 
(Madrid, Spain). Monoclonal anti-tubulin antibody 
(1:1000) from Cell Signaling (Beverly, MA, USA). All 
other reagents were analytical or culture grade purity. 
Methods 
Primary Culture of Cortical Astrocytes 
Cerebral cortical astrocytes were isolated from 
rat fetuses of 21 days gestation. Fetuses were obtained 
by caesarean section and decapitated. Cerebral 
cortices were removed and triturated 10-15 times 
through a Pasteur pipette. The cell suspension was 
filtered through nylon mesh with a pore size of 90 μm 
and diluted in DMEM containing 20% fetal bovine 
serum (FBS) supplemented with L-glutamine (1%), 
HEPES (10 mM), fungizone (1%), and antibiotics (1%). 
Cells were plated on T75 culture flask pretreated with 
poli-L-lysine. Cultures were maintained in a 
humidified atmosphere of 5% CO2/95% air at 37°C 
during 20 days. After 1 week of culture, the FBS 
content was reduced to 10%, and the medium was 
changed twice a week. By immunocytochemistry, 97% 
of cells are GFAP positive (data not shown). 
Four groups were used. Group A, control 
received Aβ40-1 peptide, Group B, Aβ40-1 peptide + 
aspirin, Group C, Aβ1-42 toxic peptide and Group D, 
Aβ1-42 toxic peptide + aspirin. Initially, we used Aβ42-1 
but due to its high cost, we assayed Aβ40-1 as we have 
used before [7].  





Cell viability of the cultures was determined by 
the MTT assay. Cells were plated in 96 well culture 
plate and incubated with Asp during 24 h at 10-11 M, 
10-9 M, 10-7 M, 10-5 M, Aβ1-42 15 µM or with Aβ1-42 15 
µM + 10-7 M Asp. After cell treatments, the medium 
was removed and the cortical cells were incubated 
with red free medium and MTT solution [0.5 mg/ml, 
prepared in phosphate buffer saline (PBS) solution] 
for 4 h at 37ºC. Finally the medium was removed and 
formazan particles were dissolved in dimethyl 
sulfoxide (DMSO). Cell viability, defined as the 
relative amount of MTT reduction, was determined 
by spectrophotometry at 570 nm.  
Trypan Blue Assay 
Trypan blue exclusion assay was used to count 
the living cells and monitor cell proliferation. 
Astrocytes were isolated and seeded at 7x104 cells/35 
mm dish. After 5 days of culture, cells were incubated 
without (control, C), with Asp (10-7 M), Aβ1-42 15 µM 
or with Aβ1-42 15 µM + 10-7 M Asp for 24 h. 1.5% 
trypan blue solution was applied to astrocytes 
cultures at room temperature for 3 min.  
Lactate Dehydrogenase (LDH) Assay 
To evaluate plasma membrane integrity, LDH 
release was determined by monitoring the leakage of 
the cytosolic LDH to the extracellular medium. LDH 
was measured spectrophotometrically at 340 nm, 
following the rate of conversion of reduced 
nicotinamide adenine dinucleotide to oxidized 
nicotinamide adenine dinucleotide. 
Caspase 3 Activity Assay 
Caspase 3 activity was measured in cytosolic 
fractions by using a highly sensitive colorimetric 
substrate, N-acetyl-Asp-Glu-Val-Asp p-nitroanilide 
(Ac-DEVD-pNA) following manufacturer´s 
instructions (CalBiochem, La Jolla, CA). Enzyme 
activity was calculated using manufacturer´s 
formulae, as pmol/min. 
Cytokine Determination, IL-1β and TNFα 
Cells were seeded, and at time of assay, the red 
phenol medium was removed and replaced by PBS 
containing 1 mg/ml bovine serum albumin (BSA), 
either in the presence or absence of Asp (10-7 M), with 
Aβ1-42 15 µM or Aβ1-42 15 µM + 10-7 M Asp). IL-1β and 
TNF-α concentration (pg/ml) were ascertained using 
ELISA kits (Pierce Biotechnology, Inc.). 
Western Blot Analysis 
Cultured cells were treated with lysis buffer and 
then mechanically degraded to release the proteins. 
Protein concentration was determined using modified 
Lowry method. Loading buffer (0.125 M Tris-HCl, pH 
6.8, 2% SDS, 0.5% (v/v) 2-mercaptoethanol, 1% 
bromophenolblue and 19% glycerol) was added to 
protein sample and heated for 5 min at 95ºC. Proteins 
(20 µg) were separated on SDS-PAGE gels and 
transferred to nitrocellulose membranes in a humid 
environment using a transfer buffer (25 mM Tris, 190 
mM glycine, and 20% methanol). Membranes were 
blocked with 5% milk in TBS-T (0.05% Tween-20) and 
incubated with primary antibodies overnight at 4ºC. 
Membranes were washed 3 times with wash buffer 
TBS-T (TBS, 0.2% Tween-20) and incubated with a 
secondary anti-rabbit IgG or anti-mouse IgG antibody 
conjugated to the enzyme horseradish peroxidase 
(HRP) for 1 h. Membranes were washed three times 
and proteins were detected using the ECL method as 
specified by the manufacturer. Autoradiography 
signals were assessed using digital image system 
ImageQuant LAS 4000 (GE Healthcare). Densitometry 
is the quantitative measurement of optical density in a 
photographic paper or photographic film, due to 
exposure to light. Concentration of protein was 
determined by densitometry analysis, expressed as 
arbitrary units relative to tubulin. 
Statistical Analyses  
All values are expressed as mean ± S.D. The 
differences between groups were determined with 
unpaired Student´s t-test. All statistical analyses were 
performed using the GraphPad Prism software 
(GrapshPad Software Inc., San Diego, CA, USA). 
Statistical significance was accepted at p ≤ 0.05.  
Results 
Asp and Cell Viability 
The role of Asp on cell viability was studied 
using MTT conversion assay. Fig. 1 shows that 
incubation with Asp at 10-11 M, 10-9 M, and 10-7 M 
significantly increased astrocyte viability vs control. 
On the other hand, Aβ1-42 significantly decreased cell 
viability (30%) compared to control cells. After 
incubation with Aβ1-42 + 10-7 M Asp, no significant 
changes were detected compared to control astrocytes 
and contrarily, an increase in cell viability was 
detected compared to cells with Aβ1-42 peptide alone.  
Trypan blue exclusion assay was used to count 
the living cells and monitor cell proliferation. 
Astrocytes were isolated and seeded at 7x104 cells/35 
mm dish. After 5 days of culture, cells were incubated 
without (control, C) or with Asp 10-7 M, Aβ1-42 15 µM 
or Aβ1-42 15 µM + Asp 10-7 M for 24 h. In control 
conditions proliferation was 0.93%, and previous 
incubation with Asp (10-7 M) increased proliferation 
by 9.53%. On the other hand, in presence of Aβ1-42 




proliferation decreased 12.96% and with Aβ1-42 + Asp 
10-7 M only decreased 5.37% (Table 1). 
 
Table 1. Astrocytes proliferation and counting living cells 
 Seeding 
cells 
5 days of 
culture 
After 24 h of 
incubation 
% Proliferation 
C 7 12.72±0.19 12.83±0.20 +0.93 
Asp (10-7 M) 7 12.70±0.11 13.91±0.16* +9.53 
Aβ 7 12.65±0.23 11.01±0.32* -12.96 
Aβ + Asp (10-7 M) 7 12.75±0.24 12.10±0.14* -5.37 
Astrocytes were isolated and seeded at 7x104 cells/35 mm dish during 5 days. At 
this time, cells were incubated without Asp (control, C), with Asp (10-7 M), Amyloid 
β1-42 (15 µM) or Amyloid β1-42 (15 µM) + Asp (10-7 M) for 24 h. Trypan blue exclusion 
was used to count the living cells and monitor cell proliferation. Data are mean ± 




Figure 1. Cell viability was determined by MTT assay in cells treated 
during 24 h. Astrocytes were incubated without Asp (control, C), with Asp at 
different concentrations (10-11, 10-9, 10-7 and 10-5 M), with Aβ1-42 (15 µM) or Aβ1-42 (15 
µM) + Asp (10-7 M) for 24 h. Data are means ± SD of four independent experiments 
(three different rats). *p < 0.05 vs. control. # p < 0.05 vs Aβ1-42 treated cells. 
 
LDH and Caspase 3 
Incubation of the astrocytes with Asp 10-7 M for 
24 h decreased significantly LDH values (21%) 
compared with control cells. With Aβ1-42 (15 µM) an 
increase of LDH release (55%) was detected compared 
with control cells and this data was reversed with Asp 
(10-7 M) to control values (Fig. 2A).  
Incubation with Asp 10-7 M for 24 h, decreased 
Caspase 3 activity significantly (45%) compared to 
control cells, whereas Aβ1-42 (15 µM) activity was 
increased in presence of Asp (10-7 M), and prevented 
the toxic peptide effect (Fig 2B), indicating reduction 
of apoptosis when Asp is present on the culture with 
Aβ1-42. 
Cytochrome c and Smac/DIABLO Expression  
Fig. 3A shows cytochrome c expression in 
astrocytes in primary culture. Asp decreased 
cytochrome c expression by 2.2-fold at 10-7 M. Aβ1-42 
increased cytochrome c expression compared to 
control cells. On the contrary, Asp (10-7 M) 
significantly reversed the cytochrome c increase 
expression induced by Aβ1-42. Fig. 3B shows 
Smac/Diablo expression in astrocytes in primary 
culture. Asp significantly decreased Smac/Diablo 
protein expression compared to control cells. 
Addition of Aβ1-42 significantly increased 
Smac/Diablo expression (1.3-fold) compared with 
control cells. Furthermore, Asp 10-7 M decreased 
Smac/Diablo expression induced by Aβ1-42 to control 
values. Consequently Asp addition produced a 
protective effect against the amyloid toxic peptide 
(Fig. 3). 
IL-1β and TNF-α Pro-inflammatory Cytokines 
Secretion of the pro-inflammatory mediators, 
IL-1β and TNF-α, were detected by ELISA. Fig 4 
shows that, in astrocytes, Asp (10-7 M) decreased 
1.6-fold IL-1β release compared with control values 
(Fig 4A). Conversely, Aβ1-42 addition increased 
2.5-fold IL-1β secretion compared with control cells. 
Aβ1-42 + Asp 10-7 M decreased IL-1β liberation to 
control values.  
Fig. 4B shows that Asp (10-7 M) produced a 
significant decrease of TNF-α secretion (3.1-fold) 
compared to control cells. Aβ1-42 addition increased 
TNF-α liberation 1.5-fold. Moreover, Asp (10-7 M) 
prevented this toxic effect produced by Aβ1-42 peptide. 
NF-κB and PPAR-γ Expression 
NF-κB is a transcription factor that regulates 
positively gene expression of pro-inflammatory 
proteins. Fig. 5A shows that Asp decreased this 
protein expression about 1.25-fold compared to 
control astrocytes. When Aβ1-42 was added an increase 
(1.5-fold) of this transcription factor was detected 
compared to control results. Asp (10-7 M) addition 
returned NF-κB to control values.  
PPARs family regulates negatively gene 
expression of pro-inflammatory proteins. Fig. 5B 
shows PPAR-γ expression in astrocytes in culture. 
Asp increased PPAR-γ expression 1.5-fold at 10-7 M. 
Addition of Aβ1-42 decreased 1.6-fold this 
transcription factor compared to control results. Asp 
(10-7 M) addition returned PPAR-γ expression to 
control values.  
COX-2 and iNOS Expression 
In Fig. 6, we detected a reduction of COX-2 
(panel A) expression after addition of Asp (10-7 M) 
compared with control values. The presence of the 
toxic peptide Aβ1-42 increased the expression of COX-2 
that was reversed by the incubation with Asp 10-7 M 
to control values. On the contrary, no changes were 
detected in COX-1 expression at any experimental 
condition (Data not shown). Fig. 6 (panel B) 
demonstrates a significand decrease in iNOS protein 
expression after Asp 10-7 M addition compared to 




control. Aβ1-42 produced a significant increase of iNOS 
expression. On the other hand, the presence of both 
the toxic peptide and Asp 10-7 M reduced significantly 
iNOS expression compared to Aβ1-42.  
Expression of CU/ZN-SOD and Mn-SOD 
Proteins 
In astrocytes, Asp 10-7 M increased Cu/Zn-SOD 
(panel A) and Mn-SOD (panel B) expression 
compared to control cells (Fig. 7). In the presence of 
the Aβ1-42 toxic peptide, a decrease of both proteins 
compared with control values was reversed by Asp. 
 
 
Figure 2. Lactate dehydrogenase and caspase 3 activity. Astrocytes were incubated without Asp (control, C), with Asp (10-7 M), Aβ1-42 (15 µM) or Aβ1-42 (15 µM) + Asp 
(10-7 M) for 24 h. Panel A: Lactate dehydrogenase from supernatants of astrocytes. Panel B: Caspase 3 activity. Data are means ± SD of four independent experiments (four 
different rats). *p < 0.05 vs. control cells. #p < 0.05 vs. Aβ1-42 treated cells.  
 
 
Figure 3. Cytocrhome c and Smac/Diablo expression. Astrocytes were incubated without Asp (control, C), with Asp (10-7 M), Aβ1-42 (15 µM) or Aβ1-42 (15 µM) + Asp 
(10-7 M) for 24 h and collected to determine Cytocrhome c (panel A) or Smac/Diablo (panel B) protein expression by Western-blot. A representative immunoblot is shown in 
the top panel. Data are means ± SD of four independent experiments (four different rats). *p < 0.05 vs. control cells. #p < 0.05 vs. Aβ1-42 treated cells. 
 
 
Figure 4. IL-1β and TNF-α determination. Astrocytes were incubated without Asp (control, C), with Asp (10-7 M), Aβ1-42 (15 µM) or Aβ1-42 (15 µM) + Asp (10-7 M). Cell 
culture supernatants were harvested and IL-1β (Panel A) and TNF-α (Panel B) were determined by ELISA. Values are means ± SD from four independent experiments (four 
different rats). *p < 0.05 vs control. #p < 0.05 vs. Aβ treated cells. 





Figure 5. NF-ᴋB and PPAR-γ expression. Astrocytes were incubated without Asp (control, C), with Asp (10-7 M), Aβ1-42 (15 µM) or Aβ1-42 (15 µM) + Asp (10-7 M) for 24 
h and collected to determine NF-ᴋB (panel A) or PPAR-γ (panel B) protein expression by Western-blot. A representative immunoblot is shown in the top panel. Data are means 
± SD of four independent experiments (four different rats). *p < 0.05 vs. control cells. #p < 0.05 vs. Aβ1-42 treated cells. 
 
Figure 6. COX-2 and iNOS expression. Astrocytes were incubated without Asp (control, C), with Asp (10-7 M), Aβ1-42 (15 µM) or Aβ1-42 (15 µM) + Asp (10-7 M) for 24 h 
and collected to determine COX-2 (panel A) or iNOS (panel B) protein expression by Western-blot. A representative immunoblot is shown in the top panel. Data are means 
± SD of four independent experiments (four different rats). *p < 0.05 vs. control cells. #p < 0.05 vs. Aβ1-42 treated cells. 
 
Figure 7. Cu/Zn-SOD and Mn-SOD expression. Astrocytes were incubated without Asp (control, C), with Asp (10-7 M), Aβ1-42 (15 µM) or Aβ1-42 (15 µM) + Asp (10-7 M) 
for 24 h and collected to determine Cu/Zn-SOD (panel A) or Mn-SOD (panel B) protein expression by Western-blot. A representative immunoblot is shown in the top panel. 
Data are means ± SD of four independent experiments (four different rats). *p < 0.05 vs. control cells. #p < 0.05 vs. Aβ1-42 treated cells. 
 
Discussion 
In this study we show that aspirin, at low-doses, 
protects from Aβ1-42 toxic peptide actions in astrocytes 
in primary culture, indicant the convenience to use 
low doses to obtain better benefices of aspirin. The 
aspirin increases cell viability and proliferation, 
decreases apoptosis (Caspase 3, Cyt c and Smac/ 
Diablo) and necrosis (LDH), in the presence or 
absence of Aβ1-42 peptide. Moreover, the aspirin 
decreases pro-inflammatory mediators (IL-β and 
TNF-α) and NF-κB expression and increases anti- 




inflammatory PPAR-γ protein after addition of Aβ1-42. 
As also inhibits COX-2 and iNOS without changes in 
COX-1 expression and increases anti-oxidant proteins 
(Cu/Zn-SOD and Mn-SOD) expression in the 
presence or absence of Aβ1-42. 
The role of astrocytes in the brain has been 
reviewed [23,24,25]. It is reported that astrocytes 
protect neurons against Aβ-amyloid peptide, 
decreasing inflammation, and oxidative stress, and 
increasing cell viability and mitochondrial biogenesis 
[7,8,26].  
Low-dose of aspirin has been reported to reduce 
the incidence of Alzheimer’s disease [27] and also the 
donation of its acetyl group to molecules that 
suppress protein aggregation in neurodegenerative 
diseases, including AD [28]. This mechanism could be 
implicated in the astrocytic protection observed in our 
study. Aβ1-42 peptide induces reduction in cell 
viability and increases apoptosis by cytochrome c and 
Smac/Diablo pathways [7,29]. However, 
simultaneous treatment with aspirin of Aβ1-42 treated 
cells protects them from neurotoxicity [29]. Reactive 
gliosis increases glial fibrillary acidic protein (GFAP) 
in AD where it is highly expressed and remarkably, 
aspirin produces a reduction in GFAP synthesis by 
blocking NF-κB in astrocytes culture [30]. It is 
reported that high doses aspirin can help reduce 
chronic AD inflammation [30]. However, our results 
show that aspirin, at low concentration (10-7 M), 
increases cell viability, diminishing necrosis and 
apoptosis. Burke et al. (2006) [31] reported that human 
daily ingestion of aspirin, 80 to 350 mg, produces 
plasma salicylate levels of 2.4 to 9.7 µg/ml, 
corresponding to 1.3 × 10-6 to 5.4 x 10-5 M of aspirin in 
the culture medium [31]. According to these results, 
the concentrations used in our experiments 
correspond to doses lower than 70 mg/day, 
considered as low doses of aspirin [32]. However, 
aspirin increases apoptosis in gastric mucosal cell line 
in a caspase-dependent manner through Smac/Diablo 
pathway [33]. Our results differ due to aspirin 
concentration used. Redlak et al. (2005) [33] used a 
concentration of 4 × 10-2 M whereas in our study we 
used 10-7 M.  
Our results indicate that low concentrations of 
aspirin may decrease apoptosis as opposed to high 
doses, protecting without increasing the adverse 
mechanisms observed in other paper. 
After Aβ1-42 addition, we detected an increase in 
COX-2 without changes in COX-1 expression. Both 
COX proteins could lead to adverse cellular effects 
derived from TXA2 and prostacyclin biosynthesis. 
Using LPS (bacterial lipopolysaccharide) to determine 
COX isoform expression in astrocytes, Font-Nieves et 
al. (2012) [34] showed a strong induction of COX-2 
through an NF-κB-dependent mechanism [34]. In 
chronic inflammation and in the progression of 
neurodegenerative diseases, NF-κB activation plays 
an important role in astrocytes in primary culture [35], 
according to previous data obtained in our laboratory 
indicating that Aβ addition is also associated with an 
increase in NF-κB activity in astrocytes [7]. Lee et al. 
(2018) [36], have indicated that downregulation of 
inflammatory molecules such as iNOS and different 
cytokines (TNF-α, IL-1β and IL-6) could be a 
consequence of the NF-κB and MAP kinases 
inhibition in astrocytes [36]. Furthermore, NF-κB 
binding sites are present in the promoters of iNOS 
and COX-2 and are essential to modulate their 
transcription [37,38]. Results of Yao et al. (2014) [39] 
demonstrated that aspirin normalizes COX-2 and 
iNOS over-expression in astrocytes in part through 
inhibition of the NF-κB pathway [39]. As these 
authors indicated, we show a reduction in the 
expression of iNOS, COX-2 and NF-κB in the presence 
of aspirin.  
Aspirin has additional targets in humans, 
besides the cyclooxygenases. Salicylic acid (SA), the 
primary metabolite of aspirin, binds human 
glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and suppresses nuclear translocation and 
cell death [40]. It is known that GAPDH plays an 
important role in neurodegenerative diseases, 
including AD [41]. 
In neurodegenerative diseases such as AD, 
treatment with non-steroidal anti-inflammatory drugs 
(NSAIDs) has been reported [42] and COX-1 and 
COX-2 are the targets of those drugs. Furthermore 
both COX isoforms regulate PPARγ activity through 
prostaglandin synthesis [43]. Also, PPARγ has been 
shown to inhibit the expression of proinflammatory 
genes, such as iNOS [44,35] and has several inhibitory 
effects on inflammation, including reduction of NF-κB 
transcriptional activities and promotes 
anti-inflammatory mediators [43]. Potent synthetic 
antidiabetics such as rosiglitazone are agonists for 
PPAR-γ [45,46] and many NSAIDs are also PPAR-γ 
agonists [47]. Furthermore, reduction of Aβ induced 
by indomethacin or naproxen by inhibiting BACE1 
(beta-site APP-cleaving enzyme 1) activity occurs in a 
PPAR-γ dependent manner [48]. In our study, we 
detected a decrease of PPAR-γ expression after Aβ 
addition that was reversed by treatment with aspirin. 
It is possible that aspirin could inhibit Aβ synthesis 
through the increment of PPAR-γ. 
In this study we also investigated the possible 
antioxidant properties of aspirin using Aβ1-42 toxic 
peptide as a model. We showed an increase 
expression of Mn-SOD and Cu/Zn-SOD proteins after 
aspirin addition in culture of astrocytes with and 




without the toxic peptide. In agreement with our 
results, Dairam et al. (2006) [49] have demonstrated 
the antioxidant and neuroprotective effects of NSADs 
in an AD rat model [49]. Furthermore, aspirin-elicited 
lipoxin A4 inhibited ROS synthesis induced by LPS in 
microglial cells [50]. Also, aspirin minimizes the effect 
of free radicals induced by LPS in rat dopaminergic 
neurons [51]. Liu et al. (2017) [52] indicated that 
aspirin at doses of 75 and 100 mg/day, similar to that 
used in our study, stimulates the levels of superoxide 
dismutase (SOD). On the other hand, production of 
L-NMMA in microcirculation is inhibited by aspirin, 
due to cyclooxygenase inhibition or SOD increase 
[53,54].  
Also, aspirin exerts pro-oxidant effects on 
Mn-SOD-deficient yeast cells causing apoptosis with 
mitochondrial involvement [55]. Furthermore, aspirin 
on focal cerebral ischemia-reperfusion rats reduced 
MDA content [56].  
Conclusion  
In conclusion, our results indicate that aspirin, at 
low doses, prevents toxic effects induced by Aβ1-42 
peptide in astrocytes in primary culture, increasing 
cell viability and proliferation while decreasing 
apoptosis and necrosis. The key finding of our study 
is that aspirin at low doses prevents oxidative stress 
and inflammation induced by Aβ1-42 toxic peptide. So, 
the administration of low doses of aspirin could be 
useful in AD patients (Fig. 8).  
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